KPIs & Operating Metrics(New)
Active Patients By RegionActive Patients By Region AnnualActive Patients TotalActive Patients Total, AnnualAsset Allocation By Category %Breakdown Of AssetsCost Of RevenuesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome Before Taxes By RegionLong Lived Assets By RegionLong Lived Assets By Region AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenuePrescriptions Received By RegionPrescriptions Received By Region AnnualPrescriptions Received By Region Annual, TotalPrescriptions Received TotalProperty And Equipment, NetR&D And Clinical Trial Expenses By ProgramReceivables And Prepaid ExpensesRevenue By Customer'S LocationRevenue By Customer'S Location %Revenue By Customer'S Location AnnualRevenue By Customer'S Location Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

NovoCure (NVCR) Gross Profit (2014 - 2026)

NovoCure recorded quarterly Gross Profit of $135.1 million in Q1 2026, up 2.22% quarter-over-quarter from $132.2 million in Q4 2025, and up 16.01% year-over-year from $116.5 million in Q1 2025.

NovoCure's Gross Profit history runs 13 years deep, the most recent figure standing at $135.1 million for Q1 2026.

  • In Q1 2026, Gross Profit rose 16.01% year-over-year to $135.1 million; the TTM figure through Mar 2026 stood at $507.1 million (up 5.72% YoY), while the FY2025 annual figure was $488.5 million, up 4.37% from the prior year.
  • Gross Profit came in at $135.1 million for Q1 2026 at NovoCure, up from $132.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $135.1 million in Q1 2026 to a low of $92.0 million in Q2 2023.
  • A 5-year average of $111.5 million and a median of $112.4 million in 2022 frame the typical range for Gross Profit.
  • Across the five-year window, Gross Profit retreated 18.09% in 2023 and rose 26.25% in 2024, its largest moves.
  • NovoCure's Gross Profit stood at $99.5 million in 2022, then climbed by 1.69% to $101.2 million in 2023, then grew by 26.25% to $127.8 million in 2024, then gained by 3.44% to $132.2 million in 2025, then grew by 2.22% to $135.1 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods registered $135.1 million, $132.2 million, and $122.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.